President Trump announced on Wednesday the nomination of Dr. Heidi Overton to serve as the next commissioner of the Food and Drug Administration (FDA). Overton currently serves as a physician and deputy assistant to the president for domestic policy at the White House. The nomination follows the resignation of the previous commissioner, Dr. Marty Makary, in May.
Overton previously completed a general surgery residency at Johns Hopkins University School of Medicine and earned her medical degree from the University of New Mexico. During the first Trump administration, she served as a White House fellow. More recently, she has worked as deputy director of the White House Domestic Policy Council, where she was involved in drafting an executive order regarding vaccines.
In his announcement on Truth Social, the president stated that Overton will work with Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services head Dr. Mehmet Oz. The president's stated goals for the FDA under her leadership include clinical trial reforms, accelerating cures, and lowering drug prices. Secretary Kennedy reportedly described Overton's advice as reliable during a recent meeting in the Oval Office.
If confirmed by the Senate, Overton will replace acting commissioner Kyle Diamantas. The leadership transition follows internal disagreements at the FDA that led to Dr. Makary's departure. According to a source familiar with the matter, Makary resigned due to disputes regarding the approval of flavored e-cigarettes, which he reportedly opposed despite pressure from other administration members. Critics of flavored e-cigarettes have expressed concern that these products are designed to attract children.
The nomination signals a specific policy direction for clinical trials and pharmaceutical pricing. If Overton implements the administration's stated goals, pharmaceutical companies and researchers would see changes in the "Clinical Trial Reforms" mentioned by the president. Additionally, consumers may see shifts in the regulation of nicotine products, following the reported internal debate over flavored e-cigarettes that preceded this nomination. These regulatory decisions influence the business operations of thousands of medical and food manufacturing companies.
The confirmation process will determine when Overton assumes full authority over the agency's 18,000-plus employees. Until a permanent commissioner is confirmed by the Senate, the agency remains under acting leadership, which can affect the pace of long-term regulatory planning. The next steps involve a formal nomination submission to the Senate, followed by committee hearings and a floor vote. No specific date for these proceedings has been reported.